Clinical Research Directory
Browse clinical research sites, groups, and studies.
Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Sponsor: Hefei Cancer Hospital of the Chinese Academy of Sciences
Summary
This study aims to evaluate the efficacy and safety of interferon-gamma combined with camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma. Based on previous mechanistic research and preliminary clinical data, this trial intends to generate high-level evidence for this therapeutic strategy, which may improve the treatment landscape for patients with locally advanced esophageal squamous cell carcinoma.
Official title: Study of Efficacy and Safety of Interferon Gamma Combined With Camrelizumab for Neoadjuvant Therapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
84
Start Date
2026-03-20
Completion Date
2028-12-31
Last Updated
2026-08-26
Healthy Volunteers
No
Interventions
Interferon-γ
1,000,000 IU administered intravenously on Day 1 of each 3-week cycle for a total of 3-4 cycles.
Camrelizumab
200 mg administered intravenously on Day 1 of each 3-week cycle for a total of 3-4 cycles.
Locations (2)
Hefei Cancer Hospital, Chinese Academy of Sciences
Hefei, Anhui, China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China